RCKT vs RGNX
RCKT: Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders. RGNX: Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with major pharma.
Side-by-side fundamentals
| Metric | RCKT | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.25 | $9.71 | |
| Market cap as of 2026-07-30 | $355M | $502M | |
| PEG as of 2026-07-30 | n/a | -0.02 | |
| Net margin as of 2026-07-30 | n/a | -330.2% | |
| Gross margin as of 2026-07-30 | n/a | +68.2% | |
| Operating margin as of 2026-07-30 | n/a | -292.3% | |
| ROE as of 2026-07-30 | -70.8% | -232.5% | RCKT higher |
| ROA as of 2026-07-30 | -59.6% | -61.0% | RCKT higher |
| Debt / equity as of 2026-07-30 | 0.09 | 8.41 | RCKT lower |
| Revenue growth (YoY) as of 2026-07-30 | n/a | -44.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +14.8% | |
| Beta as of 2026-07-30 | 0.47 | 0.92 | |
| 1-year return as of 2026-07-27 close | +3.5% | +8.4% | RGNX higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.